NEW YORK, May 4, 2011 /PRNewswire/ — Reportlinker.com announces
that a new market research report is available in its
catalogue:
Triple Analysis: Leukemia, Lymphoma and Pancreatic Cancer
http://www.reportlinker.com/p0284821/Triple-Analysis-Leukemia-Lymphoma-and-Pancreatic-Cancer.html
This triple analysis focuses on cancer drug development
strategies in Leukemia, Lymphoma and Pancreatic Cancer. Each of
these three individual parts is evaluated according to standardized
criteria in a five pillar pipeline drug assessment methodology to
compare drug development strategies in oncology. This makes it easy
to find and compare analysis not only within one single cancer
focus area but also between different areas.
Below is a short synopsis of each part included in this
report:
Part I: Leukemia
The leukemia report part comprises defined and up to date
development strategies for 313 leukemia drugs within the portfolio
of 186 investigators, from Ceased to Marketed. This part
extensively analyses their 204 identified drug targets, organized
into 193 drug target strategies, and assesses them in eight
different compound strategies and and eight subindications of
leukemia.
This part is based on the following publication:
A Decision Support Tool for Optimizing The Leukemia Pipeline:
From Research and Development to Market
Part II: Lymphoma
The lymphoma report part includes defined and up to date
development strategies for 176 lymphoma therapeutic drugs (>230
projects) within the portfolio of 106 investigators, from Ceased to
Marketed. In total the report assesses five different
sub-indications of lym
‘/>”/>
SOURCE
